Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser <i>v.</i> mood stabiliser alone
Mauricio Tohen(University of New Mexico), Joseph R. Calabrese(Case Western Reserve University), S. Nassir Ghaemi(Unknown), David J. Kupfer(University of Pittsburgh), Carlos A. Zarate(National Institute of Mental Health), Charles L. Bowden(Texas Tech University), Robert W. Baker(Eli Lilly (United States)), Richard C. Risser(Eli Lilly (United States)), Peter D. Feldman(Eli Lilly (United States)), Trisha Suppes(The University of Texas Southwestern Medical Center), Angela R. Evans(Eli Lilly (United States)), K. N. Roy Chengappa(University of Pittsburgh)
Cited by 328
Related Papers
Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder
|Bipolar Disorders|2018|1.8k
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation
|Psychological Medicine|2004|989
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
|New England Journal of Medicine|2007|925
The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders
|American Journal of Psychiatry|2013|754
Screening for depression in primary care with Patient Health Questionnaire-9 (PHQ-9): A systematic review
|Journal of Affective Disorders|2020|704